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BRIEF REPORT
Risk of Infection Associated With Subsequent
Biologic Agent Use After Rituximab: Results From a
National Rheumatoid Arthritis Patient Registry
LESLIE R. HARROLD,1 GEORGE W. REED,1 CHITRA KARKI,2 ROBERT MAGNER,3
ASHWINI SHEWADE,4 ANI JOHN,4 JOEL M. KREMER,5 AND JEFFREY D. GREENBERG6
Objective. To assess whether the time between the last rituximab infusion and initiation of a different biologic agent
influenced infection risk in patients with rheumatoid arthritis (RA).
Methods. Patients with RA who newly initiated rituximab within the Consortium of Rheumatology Researchers of North
America registrywere included if they switched to a nonrituximab biologic agent and had‡1 followup visit within 12months of
switching. Patientswere categorized by duration of time between their last rituximab infusion and initiation of a subsequent bio-
logic agent (£5 months, 6–11 months, and ‡12 months). The primary outcome was time to first infectious event. Adjusted Cox
regressionmodels estimated the association between time to starting a subsequent biologic agent and infection.
Results. A total of 44 overall infections (7 serious, 37 nonserious) were reported during the 12-month followup in the
215 patients included in this analysis (104 switched at £5 months, 67 at 6–11 months, and 44 at ‡12 months). Median
(interquartile range) time to infection was 4 (2–5) months. Infection rates per patient-year in the £5-month, 6–11-month,
and ‡12-month groups were 0.34 (95% confidence interval [95% CI] 0.22–0.52), 0.30 (95% CI 0.17–0.52), and 0.41 (95%
CI 0.22–0.77), respectively. After adjustment, time to switch to a subsequent biologic agent was not associated with infec-
tion, which remained unchanged when number and rate of rituximab retreatments were included in the models.
Conclusion. In this real-world cohort of patients with RA, infection rates ranged from 0.30 to 0.41 per patient-year,
with no significant difference in the rate between patients who initiated a subsequent biologic agent earlier versus
later after rituximab treatment.
Introduction
Patients with rheumatoid arthritis (RA) have an increased
risk of infection compared with the general population
due to extended use of disease-modifying antirheumatic
drugs (DMARDs) and biologic agent therapy, as well as
the disease itself (1). The safety of switching between bio-
logic agent therapies is an important consideration, partic-
ularly regarding the risk of infection. Although such risk
is well documented when switching within a class (e.g.,
cycling between different tumor necrosis factor inhibitors
[TNFi]) (2–4), limited data exist on infection rates when
switching between biologic agent classes, particularly in
patients who switched to a biologic agent with a different
mechanism of action after rituximab.
Rituximab is an anti-CD20 monoclonal antibody with a
unique mechanism of action that targets and depletes
CD201 B cells. Rituximab (2 3 1,000 mg, 2 weeks apart,
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every 24 weeks or based on clinical evaluation) is approved
in combination with methotrexate for the treatment of
patients with RA who have had an inadequate response to$1
TNFi. Immunosuppression due to prolonged B cell depletion
from repeated doses of rituximab may be associated with an
increased risk of infection, both with persistent rituximab
treatment and due to residual effects of rituximab when
switching to a subsequent biologic agent (5).
Currently, little is known about safety outcomes when
switching between classes of biologic agents. Of particular
interest is the time from last rituximab dose to the first dose
of the subsequent nonrituximab biologic agent. Additionally,
in clinical trial settings, patients typically receive repeat
doses of rituximab every 4–6 months, as needed; however,
the rate and number of rituximab retreatments vary in real-
world clinical practice. Understanding how both the dura-
tion of time between rituximab and a subsequent biologic
agent and the frequency of rituximab use may impact safety
outcomes can assist treatment decisions in clinical practice.
The objective of this study was to assess whether time
between the last rituximab infusion and the switch to a
biologic agent with a different mechanism of action, as
well as the intensity of rituximab use (rate and number of
retreatments), influenced risk of infection in a real-world
clinical setting in patients with RA.
Patients and methods
Study design and population. The Consortium of Rheu-
matology Researchers of North America (CORRONA) reg-
istry is an independent, prospective, observational cohort
of patients with RA recruited at more than 160 private and
academic practice sites in the US, with more than 600 par-
ticipating rheumatologists. As of May 30, 2015, data on
more than 40,989 patients with RA have been collected.
Inclusion criteria for this analysis were diagnosis of RA at
any time between March 1, 2006 and March 3, 2014; first-
time initiation of rituximab within CORRONA; subsequent
initiation of a nonrituximab biologic agent after rituximab
use, with no other biologic agents used during the interim;
$1 followup appointment within 12 months after subse-
quent biologic agent initiation; and available data on rituxi-
mab infusion dates to calculate the duration of time between
the switch from rituximab to a subsequent biologic agent.
Analytic design and cohort. The analytic design is illus-
trated in Supplementary Figure 1 (available on the Arthritis
Care & Research web site at http://onlinelibrary.wiley.com/
doi/10.1002/acr.22912/abstract). First-time initiators of ritux-
imab in CORRONA who initiated a subsequent biologic agent
after rituximab discontinuation were included. Patients were
categorized by the duration of time between their last rituxi-
mab infusion and the switch to a subsequent biologic agent
(#5 months, 6–11 months, and $12 months). Patients were
followed up from the time they initiated the subsequent bio-
logic agent (index date) to the time of the first infectious event
(infectious events occurring within 90 days after the discon-
tinuation or switch were counted as an event). Followup
ended with the first infectious event or with the earliest of the
following: 12-month elapse, discontinuation or switch of the
subsequent biologic agent, switch back to rituximab, or exit
from CORRONA.
Assessments and outcomes. The primary outcomes
were time to infection and infection rates by patient cate-
gory. The effect of the number and rate of rituximab re-
treatment prior to the index date (the time of initiation of a
subsequent biologic agent) on risk of infection was also
evaluated.
Data on infection were collected by rheumatologists at
routine visits in CORRONA, at both enrollment and fol-
lowup. Serious infections were defined as those requiring
intravenous antibiotics or hospitalization. For time to all
infections, the time to first infection was used and for seri-
ous infections, the time to first serious infection was used.
Physicians reported whether the patient ever had the
infection and the year (month and year at followup) of its
occurrence. If the patient had the infection more than
once in the past, the year (month and year at followup) of
the most recent occurrence was collected. For each infec-
tion type, rheumatologists reported pathogen types and
whether the patient was hospitalized or received paren-
teral antibiotics.
Statistical analysis. Patient demographic and clinical
characteristics at baseline (the time of initiation of a subse-
quent biologic agent) were compared across patient
Significance & Innovations
 In a real-world setting in patients with rheumatoid
arthritis, duration of time between the last rituxi-
mab infusion and the switch to a biologic agent
with a different mechanism of action was not asso-
ciated with an increased risk of infection.
 The rate and number of rituximab treatments did
not influence the risk of infection associated with
subsequent biologic agent use.
 For patients not responding to rituximab, switching
to a different biologic agent may represent an appro-
priate therapeutic option, rather than delaying treat-
ment due to perceived concerns regarding residual
effects of rituximab and risk of infection.
 These results may inform clinical decisions regarding
safety concerns when considering a switch between
classes of biologic agents.
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Table 1. Baseline characteristics, comorbidities, and medication history*
Time to switch to a subsequent biologic agent
Characteristic
£5 months
(n5104)
6–11 months
(n567)
‡12 months
(n5 44) P
Age, mean6SD years 55.66 11.1 57.96 11.7 57.86 12.3 0.36
Women 75.7 83.6 68.2 0.17
Time to switch, median (IQR) months 3.5 (2–5) 7 (6–9) 17 (15–24) NA
White 92.3 94.0 93.2 0.94
Duration of RA, mean6SD years 13.369.6 16.36 9.9 15.86 9.6 0.12
BMI, mean6SD kg/m2 30.967.8 29.66 8.0 31.36 8.0 0.46
Insurance†
Private 80.8 77.6 72.7 0.53
Medicare 26.0 46.3 45.5 , 0.01
Medicaid 6.7 6.0 9.1 0.83
No insurance 0.0 1.5 0.0 0.52
Medical history
Serious infections 6.5 11.5 9.8 0.51
Diabetes mellitus 12.5 11.9 11.4 1.00
Lung disease/pulmonary fibrosis 3.8 6.0 4.5 0.91
Liver disorder/hepatic events 5.8 7.5 4.5 0.87
Malignancy 13.5 10.5 9.1 0.75
Cardiovascular disease 6.7 14.9 11.4 0.21
Current smoker 23.3 9.0 25.0 0.03
RF seropositive‡ 63.6 67.6 77.8 0.44
ACPA seropositive‡ 57.6 59.1 75.0 0.60
CDAI, median (IQR) 24.0 (14.0–34.5) 21.0 (12.8–28.5) 21.3 (13.5–29.9) 0.13
TJC (0–28), median (IQR) 9.0 (3.0–15.0) 6.0 (1.0–10.0) 5.0 (1.5–10.0) 0.03
SJC (0–28), median (IQR) 5.0 (2.0–10.0) 6.0 (2.0–8.0) 4.0 (1.0–12.0) 0.76
Patient pain (0–100), mean6SD 55.26 25.9 55.86 24.1 52.86 28.3 0.83
DAS28-CRP, mean6SD‡ 4.76 1.4 4.56 1.7 4.16 1.5 0.27
M-HAQ score, mean6SD 0.76 0.5 0.76 0.5 0.66 0.5 0.58
Medication history
Currently receiving prednisone,
no. (%)
47 (45.2) 34 (50.7) 21 (47.7) 0.77
No. of prior DMARDs, including
current, median (IQR)
2 (1–3) 2 (1–3) 2 (2–3.5) 0.73
No. of prior biologic agents,
excluding rituximab
0 1.9 1.5 11.4 0.07
1 21.2 22.4 27.3 0.07
$2 76.9 76.1 61.4 0.07
Rituximab retreatments, mean6SD 1.56 2.2 1.56 1.9 1.16 1.7 0.54
No. of rituximab retreatments
0 52.9 40.3 50.0 0.44
1 16.4 19.4 22.7 0.44
$2 30.8 40.3 27.3 0.44
Rate of rituximab treatment
per year, mean6SD
0.9561.2 0.726 0.7 0.376 0.4 , 0.01
* Values are the percentage, unless indicated otherwise. Baseline was defined as the time of initiation of the subsequent
biologic agent. IQR5 interquartile range; NA5not applicable; RA5 rheumatoid arthritis; BMI5 body mass index;
RF5 rheumatoid factor; ACPA5 anti–cyclic citrullinated peptide antibody; CDAI5Clinical Disease Activity Index;
TJC5 tender joint count; SJC5 swollen joint count; DAS28-CRP5Disease Activity Score in 28 joints using the C-reactive
protein level; M-HAQ5modified Health Assessment Questionnaire; DMARDs5disease-modifying antirheumatic drugs.
† Insurance categories were not mutually exclusive, and patients may have had dual coverage.
‡ Laboratory measures were not mandated by the registry protocol and were not obtained in routine clinical practice.
In the #5-month, 6–11-month, and $12-month categories, respectively, n5 66, n537, and n527 for RF; n5 33,
n5 22, and n5 12 for ACPA; and n545, n5 33, and n5 21 for DAS28-CRP.
groups. Kaplan-Meier analyses estimated the time to
infection and cumulative infection rates for each patient
group. A Cox regression model estimated the unadjusted
association between the time to the switch to a subsequent
biologic agent and infection. A multivariable model esti-
mated the association between the time to the switch to a
subsequent biologic agent and infection, adjusted for
potential confounders. Potential confounders (measured
at baseline and defined as characteristics that differed by
time to initiation and were associated with infection in
the unadjusted models) were included in the model, and
the adjusted hazard ratio (HR) for time to initiation was
estimated. Potential confounders included disease activity
assessments, age, sex, duration of RA, smoking status,
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medical history variates, and number of prior nonbiologic
DMARDs and nonrituximab biologic agents. The number
and rate of rituximab retreatments per year were added to
the model regardless of the unadjusted association with
infections.
Results
Analytic population and patient characteristics. Within
CORRONA, 215 patients switched to a subsequent biologic
agent after rituximab use and were included in the analysis
(see Supplementary Figure 2, available on the Arthritis
Care & Research web site at http://onlinelibrary.wiley.
com/doi/10.1002/acr.22912/abstract). Of these patients,
104, 67, and 44 switched to a subsequent biologic agent at
#5 months (median 3.5 [interquartile range (IQR) 2–5]),
6–11 months (median 7 [IQR 6–9]), and $12 months
(median 17 [IQR 15–24]), respectively, after their last rituxi-
mab infusion. A total of 130 patient-years were included in
this analysis (#5 months [patient-years 62.1], 6–11 months
[patient-years 43.4], and $12 months [patient-years 24.3]).
A total of 103 patients switched from rituximab to a TNFi,
and 112 patients switched from rituximab to a non-TNFi
biologic agent.
The average age of the analytic cohort was 56.8 years,
and the mean duration of RA was 14.8 years. Baseline
demographic and clinical characteristics were mostly sim-
ilar between the groups; however, patients who switched
to a subsequent biologic agent earliest (#5 months) had
higher tender joint counts, and patients who switched
later (.6 months) were more likely to have Medicare cov-
erage (Table 1). Patients in the #5-month group also
tended to be younger (although not significantly), which
may account for the less frequent Medicare coverage. A
history of serious infections was observed in 6.5%, 11.5%,
and 9.8% of patients in the #5-month, 6–11-month, and
$12-month groups, respectively. There was a significantly
lower proportion of patients who were current smokers in
the 6–11-month group compared with the #5-month and
$12-month groups (P5 0.03).
Regarding medication history, patients who switched to
a subsequent biologic agent earliest (#5 months) had a
higher rate of rituximab retreatment per year compared
with the 6–11-month and $12-month groups; however,
the mean total number of rituximab retreatments was simi-
lar across the groups (Table 1). The proportion of patients
receiving prednisone and the number of prior DMARDs
was similar across groups.
Infection rates and types. Overall, there were 44 infec-
tions reported in the 215 patients during the 12-month fol-
lowup (Table 2). There were 7 serious infections (defined
as requiring intravenous antibiotics or hospitalization) at
a rate of 0.054 events per patient-year. The overall all-
infection rates (events per patient-year) were 0.34, 0.30,
and 0.41 for the #5-month, 6–11-month, and $12-month
groups, respectively. The most common types of nonseri-
ous infections observed across all patient groups were
upper respiratory infection (n5 15), urinary tract infection
(n57), and .1 organ system infection (n53; sinusitis/
urinary tract infection [n51] and urinary tract/upper
respiratory tract infection [n5 2]). No opportunistic infec-
tions were reported.
Time to infection. Of the patients who had an infection
during the 12-month followup, the median (IQR) time to
infection was 4 (2–5) months after initiation of the subse-
quent biologic agent. The time to the first infectious event
after starting the subsequent biologic agent was similar
between patient groups (Figure 1A). The probability of
infection at 3, 6, 9, and 12 months after initiation of the
subsequent biologic agent was also unaffected by the dura-
tion of time between the last rituximab infusion and the
initiation of a subsequent biologic agent (Figure 1B).
When patients were stratified by type of subsequent
Table 2. Infection rates and types by time to the switch to a subsequent biologic agent
Time to switch
£5 months
(n5 104)
6–11 months
(n5 67)
‡12 months
(n5 44) Total
Total duration of followup,
patient-years
62.08 43.38 24.25 129.71
No. of infections 21 13 10 44
Infection rate per patient-year
(95% confidence interval)
0.34
(0.22–0.52)
0.30
(0.17–0.52)
0.41
(0.22–0.77)
0.34
(0.25–0.46)
Infection type, no.
Serious infections* 1 4 2 7
Nonserious infections 20 9 8 37
Upper respiratory† 9 3 3 15
Urinary tract 5 0 2 7
Multiorgan system‡ 0 2 1 3
Skin (cellulitis) 1 1 0 2
Musculoskeletal (joint bursa) 0 0 1 1
Other 5 3 1 9
* Serious infections were defined as infections requiring intravenous antibiotics or hospitalization.
† Includes bronchitis, bronchitis/other, pneumonia, sinusitis, sinusitis/bronchitis, sinusitis/upper respiratory infection,
and upper respiratory infection.
‡ Includes sinusitis/urinary tract infection and urinary tract infection/upper respiratory tract infection.
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biologic agent used (TNFi versus non-TNFi), the probabil-
ity of infection over time was not significantly different
between the patient groups (data not shown).
Association between time to the start of a subsequent
biologic agent and infection. Based on Cox regression
models, the unadjusted HRs (95% confidence interval
[95% CI]) for infection were 0.92 (0.46–1.84) and 1.20
(0.57–2.55) in the 6–11-month and $12-month groups,
respectively, relative to the #5-month group (Figure 1C).
After adjusting for potential confounders, the HRs (95%
CIs) for infection were 0.94 (0.42–2.10) and 1.09 (0.43–
2.76) in the 6–11-month and $12-month groups, respec-
tively, relative to the #5-month group, demonstrating that
there was no association between time to the switch and
infection. Addition of the number (0, 1, or ,2) and/or rate
of rituximab retreatments prior to initiation of the subse-
quent biologic agent to the models did not impact these
results (Figure 1C).
Discussion
This analysis, conducted in a large, real-world setting of
patients with established RA and moderate to high disease
activity, assessed the risk of infection based on duration of
time between switching from rituximab to another biologic
agent. Of the 215 patients who switched from rituximab to a
subsequent biologic agent, 44 infections (7 serious) were
reported during the 12-month followup. The rate of any
infection while patients were exposed to a nonrituximab
biologic agent in this study was 0.34 per patient-year, and
the rate of serious infection was 0.054 per patient-year, simi-
lar to previous reports of 0.23 to 0.58 per patient-year and
0.055 to 0.064 per patient-year, respectively (6–8). No oppor-
tunistic infections were reported, and the distribution of
nonserious infections by organ system was as expected
based on the patient population (1).
The rate of infection was compared between patients cate-
gorized by time (#5 months, 6–11 months, and$12 months)
from last rituximab infusion to initiation of a subsequent
biologic agent. The rate of infection after initiation of the
subsequent biologic agent was not significantly different
across these groups, suggesting that there was no increase in
risk of infection when switching early (within 5 months of
the last rituximab infusion) compared with switching later
($1 year after the last rituximab infusion). Additionally, the
risk of infection was adjusted for the number and rate of
rituximab retreatments and compared across patients in
the #5-month, 6–11-month, and $12-month groups. After
adjusting for the number and rate of rituximab retreatments,
the HRs for risk of infection after initiation of the subsequent
biologic agent were not significantly different across patients
in the#5-month, 6–11-month, and $12-month groups. This
lack of difference suggests that the intensity of rituximab use
prior to the switch did not influence the risk of infection
associated with the subsequent biologic agent, regardless of
the duration of time between the last rituximab infusion and
initiation of a subsequent biologic agent.
Previous studies have examined the risk of infection
when switching between biologic agents of the same class
and between classes. Switching from one TNFi to another
Figure 1. Summary of infections. A, survival analysis of the
probability of not experiencing an infection over time by time to
the switch. Estimates of time to infection and probability of infec-
tion were similar when analyzing tumor necrosis factor inhibitor
(TNFi) initiators and non-TNFi initiators separately. B, probabil-
ity of infection at 3, 6, 9, and 12 months by time to the switch.
C, unadjusted and adjusted hazard ratios (HRs) for infection rate
by time to the switch. Cox regression models were adjusted for
age, sex, duration of rheumatoid arthritis, smoking status, patient
pain, modified Health Assessment Questionnaire, Clinical Dis-
ease Activity Index, presence of subcutaneous nodules, history of
cardiovascular disease, history of liver disease, history of serious
infection, number of prior disease-modifying antirheumatic
drugs, and number of prior biologic agents (excluding rituximab
[RTX]). 95% CI595% confidence interval.
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TNFi was not associated with increased infection risk in
adjusted models (2,4). Two studies have examined the
safety of biologic agents after rituximab treatment (7,9).
One retrospective study examined 22 patients with RA
who initiated a subsequent biologic agent at a mean of 4
months (range 1–12 months); after a mean followup time of
14 months, there were no serious infections, and the dura-
tion of time between stopping rituximab and initiating a
subsequent biologic agent was unrelated to the occurrence
of nonserious infections (9). In another study, data on seri-
ous infections were collected from a cohort of 185 patients
with RA from an international rituximab clinical trial pro-
gram (7). The majority of patients were peripherally B cell
depleted when a subsequent biologic agent was initiated at
a median of 7 months after the last rituximab infusion. The
overall rate of serious infections was 0.055 per patient-year
after exposure to the subsequent biologic agent, similar to
the observed rate of 0.054 in this study.
Additionally, as in our study, the nature of the infections
reported (upper respiratory tract and urinary tract) were
consistent with typical infections seen in patients with RA
treated with DMARDs or other biologic agents.
Although the current study was based on a small cohort of
patients from an observational study, it provides a unique
opportunity to examine the impact of the timing of biologic
agent therapy on safety in patients who are likely B cell
depleted from rituximab. These results provide additional
confidence that the risk of infections is not substantially
higher in patients with a short time interval between 2 differ-
ent biologic agents. For patients needing to switch from rituxi-
mab, these data suggest that switching to another biologic
agent with the potential for suppression of disease activity is a
valid approach. Providers should therefore be encouraged to
optimize therapy according to disease activity levels after an
inadequate response to rituximab, rather than delay initiation
of another biologic agent due to concerns regarding residual
immunosuppressive effects of rituximab and the risk of
infection.
The strengths of this analysis stem from the large,
population-based nature of the CORRONA registry, repre-
senting routine care from more than 160 rheumatology clini-
cal practices in the US, allowing for generalizability of
findings. The limitations of this study include the small
sample size for analysis, limited followup, and wide 95%
CIs. Additionally, recall bias of the actual dates of the quali-
fying infection may influence the results. Further, the status
of the patients’ B cell depletion was not measured in this
analysis. Future studies will be necessary to determine
whether the peripheral B cell level after rituximab treatment
affects the safety of subsequent biologic agents.
In this sample of patients with RA, rates of infection
were consistent with previously published estimates. The
types of infections acquired were consistent with observa-
tions in patients with RA (1). Duration of time between
the last rituximab infusion and the switch to subsequent
biologic agents with different mechanisms of action did
not influence the risk of infection in this small cohort.
For patients with an inadequate response to rituximab,
switching to another class of drug 4 months after the last
infusion may be an appropriate therapeutic approach rather
than delaying treatment. Taken together, these results may
inform clinical decisions regarding safety outcomes when
switching between classes of biologic agents.
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